Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Raises 2025 Revenue and EPS Outlook After Q3 Revenue Rose 13%

Positive Impact 4 of 5 guidance Written later

IDEXX reported third quarter 2025 revenue of $1,105 million, up 13% as reported and 12% organic, and diluted EPS of $3.40, up 21%. The company raised its full-year 2025 revenue guidance to $4,270 million-$4,300 million and its EPS outlook to $12.81-$13.01, both signaling stronger expected results for shareholders.

Key points

  • Q3 2025 revenue of $1,105 million, up 13% as reported and 12% organic; CAG revenue up 14% and LPD up 17%.
  • Q3 diluted EPS of $3.40, up 21% as reported and 15% comparable; operating margin 32.1%, up 100 basis points.
  • 2025 revenue guidance raised to $4,270 million-$4,300 million from $4,205 million-$4,280 million; EPS outlook raised to $12.81-$13.01 from $12.40-$12.76.

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECNov 3, 2025, 6:34 AM ET
Accession number0001104659-25-105185

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.